证券代码：000813 证券简称：德展健康 公告编号：2025-071 德展大健康股份有限公司 三、备查文件 德展大健康股份有限公司（以下简称"公司"）第九届董事会第二次会议的 通知已于 2025 年 10 月 21 日以电子邮件方式发出；公司于 2025 年 10 月 24 日 11:00 以通讯表决方式召开。本次会议应参加会议董事 9 人，实际参加会议董事 9 人。会议由董事长魏哲明先生主持，公司全体高管列席了本次会议。本次会议 的召集、召开符合《公司法》及《公司章程》的规定。 二、董事会会议审议情况 （一）关于公司 2025 年第三季度报告的议案 公司依据 2025 年第三季度生产经营情况编制了《德展大健康股份有限公司 2025 年第三季度报告》。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 该议案审议获得通过，并已经公司审计委员会审议通过。 具体内容详见公司同日在《证券时报》《上海证券报》《中国证券报》《证 券日报》、巨潮资讯网（www.cninfo.com.cn）披露的《2025 年第三季度报告》 （公告编号：2025-072）。 第九届董事会第二次会议决议公告 本公司及董事会全体成员保证 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥111,144,059.87, representing a 4.70% increase year-over-year, but a 21.71% decrease for the year-to-date period[5]. - The net profit attributable to shareholders was -¥18,098,873.86, a significant decline of 777.27% compared to the same period last year, and a year-to-date decline of 854.37% to -¥61,025,357.03[5]. - The basic and diluted earnings per share were both -¥0.0085, reflecting a decrease of 750.00% year-over-year and 878.38% year-to-date[5]. - Total operating revenue for the current period is ¥277,500,292.60, down 21.7% from ¥354,472,693.30 in the previous period[25]. - Net profit for the current period is a loss of ¥88,537,198.97, compared to a loss of ¥8,329,156.02 in the previous period, indicating a significant decline in profitability[26]. - The company reported a basic and diluted earnings per share of -0.0288, compared to 0.0037 in the previous period[27]. Assets and Liabilities - The total assets at the end of Q3 2025 were ¥5,233,330,047.52, down 1.63% from the end of the previous year[5]. - As of September 30, 2025, the total assets of the company amounted to ¥5,233,330,047.52, a decrease from ¥5,319,833,620.49 at the beginning of the period[20]. - The company's cash and cash equivalents decreased to ¥2,365,526,990.47 from ¥2,530,699,274.17, reflecting a decline of approximately 6.5%[20]. - Total liabilities increased to ¥271,088,648.98 from ¥154,884,054.36, reflecting a significant rise in financial obligations[22]. - Non-current liabilities rose sharply to ¥160,404,041.83 from ¥45,010,236.25, indicating increased long-term financial commitments[22]. - The company's total equity decreased to ¥4,962,241,398.54 from ¥5,164,949,566.13, showing a decline in shareholder value[23]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥26,411,149.81, showing a substantial increase of 205.30%[5]. - The net cash flow from operating activities was $26,411,149.81, a significant improvement compared to a net outflow of -$25,080,901.14 in the previous period, indicating a turnaround in operational performance[30]. - The net cash flow from investing activities was -$191,552,325.58, worsening from -$110,143,377.46 in the prior period, reflecting increased investment expenditures[31]. - Cash and cash equivalents at the end of the period totaled $2,275,231,169.90, down from $2,531,158,919.42 at the end of the previous period, showing a decrease of approximately 10%[31]. - The total cash inflow from financing activities was $118,800,000.00, with cash outflow totaling $136,006,267.42, resulting in a net cash outflow of -$17,206,267.42[31]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 57,596[14]. - Xinjiang Kaidi Investment Co., Ltd. holds 19.54% of shares, totaling 409,748,445 shares, with 143,000,000 shares pledged[14]. - The top 10 shareholders include Meilin Holdings Group Co., Ltd. with 8.85% (185,672,150 shares) and Chen Zhiwenlong with 6.18% (129,500,000 shares)[14]. - Xinjiang Kaidi Mining Investment Co., Ltd. holds 4.96% (104,039,367 shares) and Zhu Ming holds 4.01% (84,073,700 shares)[15]. - The total shares held by the top 10 unrestricted shareholders amount to 409,748,445 shares[15]. - The company has not reported any changes in the top 10 shareholders due to margin trading or lending of shares[15]. Investments and Expenses - Investment losses increased by 37.58% to -¥13,980,876.41, mainly due to higher losses from investments in joint ventures[11]. - Research and development expenses decreased to ¥29,070,328.37 from ¥36,148,711.02, a reduction of 19.5%[26]. - The company reported a significant investment loss of ¥13,980,876.41, compared to a loss of ¥10,162,176.84 in the previous period[26]. - The company’s cash flow from investment activities reflects a strategic focus on growth, with substantial investments in fixed assets totaling $156,921,325.46[30]. Corporate Governance - The company plans to hold a board meeting to elect a new chairman and senior management, indicating a potential shift in governance[18]. - The company established a "Technology Innovation Development Center" to enhance its technological innovation capabilities and decision-making processes[18]. - The company has completed the cancellation of repurchased shares, aligning with legal regulations regarding share buybacks[20].

Core Insights - The NMN concept index rose by 0.95%, ranking 10th among concept sectors, with 18 stocks increasing in value, led by Te Yi Pharmaceutical, which hit the daily limit, and other notable gainers including Su Yan Jing Shen, Zhong Sheng Pharmaceutical, and Shuanglu Pharmaceutical, which rose by 5.93%, 5.22%, and 4.42% respectively [1][2] Market Performance - The NMN concept sector saw a net inflow of 181 million yuan from main funds, with 13 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow. Te Yi Pharmaceutical topped the list with a net inflow of 215 million yuan, followed by Zhong Sheng Pharmaceutical, De Zhan Health, and Shuanglu Pharmaceutical with net inflows of 51.31 million yuan, 35.94 million yuan, and 14.18 million yuan respectively [2][3] Fund Flow Ratios - Te Yi Pharmaceutical, Yaben Chemical, and De Zhan Health had the highest net inflow ratios, with rates of 17.90%, 11.09%, and 9.59% respectively [3]

Core Viewpoint - Dezheng Health (000813) hosted the "Xinjiang Drug Research and Development Innovation and Industry Exchange Seminar" on July 23, 2025, which is significant for the innovative development of the Xinjiang pharmaceutical industry [1] Group 1 - The seminar gathered experts, scholars, and industry peers to provide insights for the innovative development of the Xinjiang pharmaceutical industry, creating a more supportive environment for research and development, financial capital, and industrial policies [1] - The establishment of the company's academician expert workstation during the seminar will help gather top intellectual resources, enhance research and development capabilities, and accelerate the transformation of scientific achievements [1] - The event is expected to provide substantial support for the regional industrial environment and the long-term development of the company [1]

Group 1 - The company emphasizes the importance of the Hainan Free Trade Port construction and its development opportunities [2] - The Hainan Decheng International Medical and Health Complex project is recognized as a significant project for Hainan Province by 2025 [2] - The company plans to leverage the policies and resource advantages of the Hainan Free Trade Port while actively researching and assessing the impact of these policies on the project [2]

Market Overview - The Shanghai Composite Index closed at 3869.25 points, with a change of 0.10% [1] - The total trading volume of A-shares reached 1,280.495 billion yuan [1] Technical Analysis - A total of 175 A-shares experienced a death cross between the 5-day and 10-day moving averages [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Yuanjie Technology: 5-day MA down by 2.50% from the 10-day MA [1] - Shanshan Shares: 5-day MA down by 2.32% from the 10-day MA [1] - Zijian Electronics: 5-day MA down by 2.09% from the 10-day MA [1] Individual Stock Performance - Yuanjie Technology (688498): Increased by 3.59% with a trading turnover of 2.90% [1] - Shanshan Shares (600884): Increased by 0.22% with a trading turnover of 3.13% [1] - Zijian Electronics (301121): Decreased by 0.60% with a trading turnover of 3.19% [1] - Other notable stocks include: - WuXi AppTec (603259): Increased by 2.21% [1] - Fabon (300925): Increased by 1.67% [1] Summary of Stocks with Death Cross - Stocks with a death cross and their respective metrics include: - Yuanjie Technology: 5-day MA at 374.57 yuan, 10-day MA at 384.17 yuan [1] - Shanshan Shares: 5-day MA at 14.17 yuan, 10-day MA at 14.51 yuan [1] - Zijian Electronics: 5-day MA at 48.72 yuan, 10-day MA at 49.76 yuan [1] - The latest prices of these stocks are below their 10-day moving averages, indicating potential bearish trends [1]

Core Points - The Shanghai Composite Index is at 3876.54 points with a change of 0.29%, and the total trading volume of A-shares is 961.216 billion yuan [1] - A total of 158 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stocks with Significant Moving Average Crosses - Yuanjie Technology (688498) has a 5-day moving average of 374.30 yuan, which is 2.53% lower than its 10-day moving average of 384.03 yuan, with a current price of 357.58 yuan, down 6.89% from the 10-day average [1] - Shanshan Co., Ltd. (600884) shows a 5-day moving average of 14.14 yuan, down 2.43% from its 10-day moving average of 14.49 yuan, with a current price of 13.29 yuan, down 8.28% from the 10-day average [1] - ZhiJian Electronics (301121) has a 5-day moving average of 48.75 yuan, which is 2.05% lower than its 10-day moving average of 49.78 yuan, with a current price of 46.54 yuan, down 6.50% from the 10-day average [1] Group 2: Other Notable Stocks - WuXi AppTec (603259) has a 5-day moving average of 102.27 yuan, which is 1.97% lower than its 10-day moving average of 104.33 yuan, with a current price of 98.12 yuan, down 5.95% from the 10-day average [1] - Fabon Information (300925) shows a 5-day moving average of 25.73 yuan, down 1.78% from its 10-day moving average of 26.20 yuan, with a current price of 25.13 yuan, down 4.07% from the 10-day average [1] - Loka (603829) has a 5-day moving average of 21.29 yuan, which is 1.73% lower than its 10-day moving average of 21.67 yuan, with a current price of 20.07 yuan, down 7.37% from the 10-day average [1]

Core Viewpoint - The company is actively developing the Hainan Decheng International Medical and Health Complex project, leveraging the Hainan Free Trade Port's "medical special zone" policy to create a high-end integrated health industry model [1] Group 1: Project Development - The company has a subsidiary in Chengmai County, Hainan Province, which is responsible for the construction of the international medical and health complex [1] - The project is positioned as an international medical and health complex, relying on a secondary rehabilitation hospital and targeting health, vacation, and recuperation clientele from Chengmai and Haikou, with a nationwide reach [1] - Some main structural components of the project have already been capped, and the construction of other structural elements is progressing steadily [1] Group 2: Future Plans - The company plans to fully utilize global high-quality medical resources and actively explore potential development opportunities in Hainan [1] - The goal is to establish the complex as a high-end integrated facility centered around a "high-end international hospital," achieving an integrated high-end ecological closed-loop health industry model that encompasses "medical care, research, travel, and tourism" [1]

Core Viewpoint - The report highlights the growth of industrial enterprises in the Xinjiang Uygur Autonomous Region, indicating a significant increase in the number of large-scale industrial companies, which presents potential investment opportunities in the region's industrial sector [1] Group 1: Company Information - Listed companies mentioned include Guanghui Energy, New Natural Gas, Unified Shares, ST Haoyuan, Xinjiang Torch, Western Animal Husbandry, Tianrun Dairy, Dezhan Health, Xuefeng Technology, Chuaning Biological, Xiling Information, Lide New Energy, and Tianfu Energy [1] - The report is published by Zhiyan Consulting, a leading industry consulting firm in China, specializing in deep industry research and providing comprehensive consulting services [1] Group 2: Industry Statistics - As of January to August 2025, the number of industrial enterprises in Xinjiang reached 5,415, an increase of 477 compared to the same period last year, representing a year-on-year growth of 9.66% [1] - The industrial enterprises in Xinjiang account for 1.04% of the total number of such enterprises in the country [1] - The threshold for large-scale industrial enterprises was raised from an annual main business income of 5 million yuan to 20 million yuan starting in 2011 [1]

证券日报网讯德展健康（000813）9月29日在互动平台回答投资者提问时表示，参股公司东方略在研重 点产品VGX-3100的首个适应症(用于HPV-16和/或HPV-18相关的宫颈高级别癌前病变的治疗)Ⅲ期临床试 验已完成全部患者入组。用于HPV-16和/或HPV-18相关的肛门高级别癌前病变和阴道高级别癌前病变治 疗的两个适应症已取得国家药监局的批复，直接进入临床II期试验。 ...